Internal Medicine, Hematology & Oncology · Atlanta, GA
NPI
1689725228
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1100 Johnson Ferry Rd Ste 600
Atlanta, GA, 30342
Phone (404) 256-4777
Groups this clinician bills Medicare through
Medicare paid, 2024
$57K
944 services
Medicare patients, 2024
128
Average age 74
Drug cost, 2024
$1.4M
440 prescriptions
Company payments, 2025
$931
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kamal N Ummed was code 99213 (office e&m - established), 325 times for 78 patients. In total Kamal N Ummed billed 944 services in 14 codes, and Medicare paid $57K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-08-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 325 | 78 | $47.14 | $15K |
| 99214 Office E&M - Established | Facility | 256 | 80 | $71.35 | $18K |
| 99214 Office E&M - Established | Office | 55 | 26 | $99.44 | $5,469 |
| 99232 Hospital E&M - Subsequent | Facility | 54 | 22 | $62.00 | $3,348 |
| 99213 Office E&M - Established | Office | 54 | 30 | $68.57 | $3,703 |
| 99212 Office E&M - Established | Facility | 44 | 19 | $24.74 | $1,089 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 37 | 25 | $12.56 | $465 |
| 99231 Hospital E&M - Subsequent | Facility | 32 | 13 | $38.91 | $1,245 |
| 99215 Office E&M - Established | Facility | 29 | 18 | $109.67 | $3,180 |
| 99221 Hospital E&M - Initial | Facility | 14 | 12 | $65.19 | $913 |
By year: 2022 $61K for 1,111 services; 2023 $69K for 1,195 services; 2024 $57K for 944 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kamal N Ummed prescribed most often to Medicare patients was Gabapentin, with 36 prescriptions and refills. In total Kamal N Ummed wrote 440 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 36 | 36 | Under 11 | $280 |
| Potassium Chloride Generic | 29 | 37 | Under 11 | $235 |
| Pazopanib Hcl Generic | 22 | 22 | Under 11 | $218K |
| Dexamethasone Generic | 20 | 22 | 11 | $322 |
| Pantoprazole Sodium Generic | 19 | 35 | Under 11 | $69.36 |
| Ibrance Palbociclib | 17 | 18 | Under 11 | $283K |
| Lorazepam Generic | 15 | 15 | Under 11 | $36.96 |
| Letrozole Generic | 14 | 18 | Under 11 | $229 |
| Eliquis Apixaban | 13 | 13 | Under 11 | $7,521 |
| Jakafi Ruxolitinib Phosphate | 13 | 13 | Under 11 | $213K |
| Imatinib Mesylate Generic | 13 | 23 | Under 11 | $14K |
| Ondansetron Hcl Generic | 13 | 13 | Under 11 | $128 |
| Prochlorperazine Maleate Generic | 13 | 13 | Under 11 | $153 |
| Xarelto Rivaroxaban | 12 | 20 | Under 11 | $11K |
| Ninlaro Ixazomib Citrate | 12 | 12 | Under 11 | $159K |
Brand drugs: 103 claims; generic drugs: 337 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kamal N Ummed $931 ($931 in general payments such as food, travel and fees) from 22 companies. The largest payer was Amgen Inc. with $125.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 1 | $125 |
| Celgene Corporation BMY | 3 | $76.84 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $76.74 |
| Pfizer Inc. PFE | 3 | $71.46 |
| Genzyme Corporation SNY | 2 | $65.19 |
| Incyte Corporation INCY | 2 | $49.49 |
| Eisai Inc. 4523.T | 2 | $44.56 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $41.39 |
| TerSera Therapeutics LLC | 1 | $34.72 |
| SpringWorks Therapeutics, Inc. | 1 | $33.72 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.